Transcriptomic era of cancers in females: new epigenetic perspectives and therapeutic prospects

• Published in: Frontiers in oncology 2024-11, Vol.14, p.1464125
• Main Authors: Zhu, Runhe, Ni, Jiawei, Ren, Jiayin, Li, Dongye, Xu, Jiawei, Yu, Xinru, Ma, Ying Jie, Kou, Luan
• Format: Article
• Language: English
• Subjects: cancers; epigenetic; era; females; Oncology; transcriptomic
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2024.1464125

In the era of transcriptomics, the role of epigenetics in the study of cancers in females has gained increasing recognition. This article explores the impact of epigenetic modifications, such as DNA methylation, histone modification, and non-coding RNA, on cancers in females, including breast, cervical, and ovarian cancers (1). Our findings suggest that these epigenetic markers not only influence tumor onset, progression, and metastasis but also present novel targets for therapeutic intervention. Detailed analyses of DNA methylation patterns have revealed aberrant events in cancer cells, particularly promoter region hypermethylation, which may lead to silencing of tumor suppressor genes. Furthermore, we examined the complex roles of histone modifications and long non-coding RNAs in regulating the expression of cancer-related genes, thereby providing a scientific basis for developing targeted epigenetic therapies. Our research emphasizes the importance of understanding the functions and mechanisms of epigenetics in cancers in females to develop effective treatment strategies. Future therapeutic approaches may include drugs targeting specific epigenetic markers, which could not only improve therapeutic outcomes but also enhance patient survival and quality of life. Through these efforts, we aim to offer new perspectives and hope for the prevention, diagnosis, and treatment of cancers in females.